Brian Skorney

Shares of Intercept Pharmaceuticals Inc (NASDAQ: ICPT) continued to sell off Friday in reaction to the U.S. Food and Drug Administration's letter to physicians warning them against the company's liver disease medicine called Ocaliva. One of the main takeaways from the FDA's letter is the absence of...

Analysts at Baird Equity Research turned bearish on Regeneron Pharmaceuticals Inc (NASDAQ: REGN) as investor expectation for a recently launched drug may be too high. The firm's Brian Skorney downgrades Regeneron's stock rating from Neutral to Underperform with an unchanged $408 price target....

Neurocrine Biosciences, Inc. (NASDAQ: NBIX) investors got a pleasant surprise when the FDA approved the company’s Ingrezza drug for treatment of tardive dyskinesia (TD). While the approval itself was expected, Baird analyst Brian Skorney says the FDA’s generous labeling puts the drug at...

Sarepta Therapeutics Inc's (NYSE: SRPT) rough Tuesday carried over into Wednesday's session after the company reported a better than expected loss in its fourth quarter but expects full year sales of Exondys to fall short of what analysts were expecting. Brian Skorney of Baird commented in...

Shares of Gilead Sciences, Inc. (NASDAQ: GILD) are set to open on a new 52-week low following its lower-than-expected 2017 revenue forecast on weaker Hepatitis C sales. Gilead provided fiscal year 2017 revenue guidance of $22.5 billion–$24.5 billion, well below consensus at $27.9 billion....

Baird downgraded the shares of Theravance Biopharma Inc (NASDAQ: TBPH) to Underpeform but raised its price target to $24 from $19. The firm believes the current valuation is unsustainable given the long path to approval and the significant spend along the way. The firm sees a correction in the...

Sarepta Therapeutics Inc (NASDAQ: SRPT) and Summit Therapeutics PLC (NASDAQ: SMMT) announced a licensing deal Tuesday. Sarepta earns European commercial rights for Summit’s utophin modulation portfolio for an initial $40 million and up to $522 million in milestones and royalties....

Sarepta Therapeutics Inc (NASDAQ: SRPT) announced Tuesday that the Patent Trial and Appeal Board issued two favorable decisions for Sarepta which refused BioMarin Pharmaceutical Inc. (NASDAQ: BMRN)'s claims. In a report, Brian Skorney of Baird suggested the PTAB's ruling implies Sarepta...

Last week, Sarepta Therapeutics Inc (NASDAQ: SRPT)'s Phase 3 ESSENCE study was updated and extended from 48 to 96 weeks. To many, the extension of the endpoint signaled a lack of confidence in the study's readout, however Baird thinks otherwise. Baird's Interpretation Despite the market's bearish...

Baird's Brian Skorney reiterated Biogen Inc (NASDAQ: BIIB)'s Neutral rating with a $268 price target. The reiteration came after Biogen's roadshow. "We continue to see the firm facing headwinds towards the back half of the year as MS sales flatten and clinical data catalysts dry up," said the...